SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of competing RRP treatment Voceryq has put Precigens PAPZIMEOS in focus, with traders debating whether the new entrant will erode its sales. Bears see a direct competitive threat, while bulls point to PAPZIMEOS full approval and commercial head start and question Inovios ability to commercialize an accelerated-approval drug.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Discussion centers on Compounds institutional-market launch and treasury-backed institutional finance push, which traders view as a potential catalyst alongside the protocols planned upgrades. Optimism about COMPs limited supply and a possible breakout is tempered by complaints that it continues to lag other crypto assets.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 report and stronger-than-expected Q4 profit outlook are driving attention, with shares rising despite revenue and EPS misses. Traders are focused on subscriber growth and improved margins, while some question the rally given the earnings shortfall and higher expenses.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios shares sold off despite a quarterly earnings beat as its outlook signaled slower organic growth, prompting concerns about deceleration and softer guidance. Traders are split between viewing the drop as an overreaction and buy-the-dip opportunity, and seeing the slower outlook as outweighing the results; some remain positive on Twilios longer-term AI communications potential.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is drawing attention amid a broad selloff in Chinese equities, with traders citing the CSI 300s bear-market decline, weak domestic demand and added uncertainty around AI export restrictions. The community is divided between warnings of a prolonged downturn and views that beaten-down China shares may be nearing a base.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Attention is centered on Zebecs payroll and payments integrations, particularly the MoneyGram/Stellar connection and a reported Germany/AllUnity deployment, which bullish traders view as adoption catalysts. Skeptics counter that partnership news has yet to translate into sustained token demand or price strength, while speculation about additional Robinhood or Ripple links remains unconfirmed.

OpenAI

OpenAIs potential IPO is driving attention, with traders debating reports that the listing could slip to 2027 amid market volatility and heightened safety and legal scrutiny. The discussion is split between enthusiasm for a major AI listing and skepticism about OpenAIs valuation, cash burn, and ability to sustain growth against competitors.

Artificial Superintelligence Alliance (FET) is a cryptocurrency launched in 2018. Artificial Superintelligence Alliance has a current supply of 2,714,384,546.672 with 2,419,135,848.3909366 in circulation. The last known price of Artificial Superintelligence Alliance is 0.16707757 USD and is up 1.84 over the last 24 hours. It is currently trading on 592 active market(s) with $193,186,396.23 traded over the last 24 hours. More information can be found at https://superintelligence.io/.

Fetch.ai

FETs price action and its place in the AI-crypto trade dominate the discussion, with traders watching for a breakout and describing relative strength during broader market weakness. Bullish dip-buying and accumulation hopes coexist with frustration over lagging performance and concern that Bitcoin weakness could weigh on the token.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of whether the S&P 500 rally is broadening beyond mega-cap tech, with traders highlighting its relative strength and recent highs as evidence of rotation into the average stock. Others warn that participation remains uneven and question whether the rotation can persist, especially as technology leadership shifts.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The Crocs Brand segment refers to the United States, South Korea, China, Japan, Singapore, Canada, Germany, Great Britain, France, Malaysia, Australia, Puerto Rico, the Netherlands, Australia, India, and Ireland. The HEYDUDE Brand segment focuses on the United States. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is drawing attention after quarterly results topped expectations and management raised its outlook, citing a continuing HEYDUDE recovery and steady demand for its core brand; the news fueled a sharp rally. Traders are cheering the breakout, while others warn of profit-taking and point to continued weakness in North American sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Penumbra, Inc. Reports Third Quarter 2026 Financial Results

Penumbra, Inc. Reports Third Quarter 2026 Financial Results Penumbra, Inc. Reports Third Quarter 2026 Financial ResultsPR NewswireALAMEDA, Calif., Oct. 29, 2026 ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc.(NYSE: PEN), the world's leading thrombectomy company, today reported...

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT) Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)PR NewswireALAMEDA, Calif., Oct. 20, 2026 BOLT-DVT, a recent prospective, multicenter Investigational...

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured...

IART vs. PEN: Which Stock Is the Better Value Option?

IART or PEN: Which Is the Better Value Stock Right Now?

Reasons to Retain Penumbra Stock in Your Portfolio for Now

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

TFX vs. PEN: Which Stock Is the Better Value Option?

TFX or PEN: Which Is the Better Value Stock Right Now?

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

$PEN Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $1.07 up 10.31% YoY
• Reported revenue of $410.14M up 15.63% YoY

Stocktwits

Penumbra Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $1.07 up 10.31% YoY
• Reported revenue of $410.14M up 15.63% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $1.07 up 10.31% YoY
• Reported revenue of $410.14M up 15.63% YoY

Penumbra's net income and diluted EPS were below Q3 2025 levels, operating expenses exceeded prior-year levels, and the pending acquisition carries completion and regulatory-approval risks; FY 2026 guidance will not be provided.

Penumbra reported thrombectomy revenue growth and higher U.S. VTE revenue, revenue increases across U.S. and international markets, and a 68.3% gross profit margin, up 0.5% year over year.

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Penumbra Shares Are Rising Today — What Is The Boston Scientific Agreement?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Penumbra shareholders have the option to either receive $374 in cash or 3.8721 shares of Boston Scientific, according to the terms of the deal.</li><li>The $374 cash consideration per share is at a premium of over 24% compared to the closing price of Penumbra shares on Wednesday.</li><li>Boston Scientific stated that it expects to finance the approximately $11 billion cash portion of the transaction consideration with a combination of cash on hand and new debt.</li></ul>Penumbra Inc. (PEN) shares gained over 12% in Thursday’s opening trade after Boston Scientific Corp. (BSX) announced an agreement to acquire the global healthcare company.Boston Scientific stated that it has agreed to acquire Penumbra in a cash and stock transaction that values the latter at an enterprise value of $14.5 billion.<a href="https://stocktwits.com/symbol/BSX">Boston Scientific shares</a> were down more than 5% in Thursday’s opening session. Retail sentiment on Stocktwits around Boston Scientific trended in the ‘bullish’ territory, while users felt ‘extremely bullish’ about&nbsp;<a href="https://stocktwits.com/symbol/PEN">Penumbra</a>.<h2 class="st-heading-2">Details Of The Deal</h2>Penumbra shareholders have the option to either receive $374 in cash or 3.8721 shares of Boston Scientific, according to the terms of the deal. The $374 cash consideration per share is at a premium of over 24% compared to the closing price of Penumbra shares on Wednesday.“The addition of Penumbra can expand access for these novel technologies to more patients and customers around the world, further enhancing our revenue and margins over time with proven offerings that have a history of growth and innovation,” Boston Scientific CEO Mike Mahoney said.Boston Scientific stated that it expects to finance the approximately $11 billion cash portion of the transaction consideration with a combination of cash on hand and new debt. The acquisition is expected to be $0.06 to $0.08 dilutive to adjusted earnings per share (EPS) for Boston Scientific in the first full financial year following the close of the acquisition.<h2 class="st-heading-2">What Does Penumbra Do?</h2>Penumbra is a thrombectomy company that develops technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia.The company’s offerings, which includes computer assisted vacuum thrombectomy (CAVT), are designed to remove blood clots in patients.<a href="https://stocktwits.com/symbol/PEN">PEN stock</a> is up 13% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/PEN">BSX stock</a> is down 6%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spotify-hikes-premium-subscription-prices-12-99-us-market-spot-stock-rises/cmU1SiYR47q">Spotify Hikes Premium Plan Price Across US, Select Markets — SPOT Stock Rises Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Penumbra logo is seen displayed on a smartphone screen

Boston Scientific stated that it has agreed to acquire Penumbra in a cash-and-stock transaction that values the latter at an enterprise value of $14.5 billion.

Boston Scientific Corp.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PEN News